DAIC
APRIL 7, 2024
milla1cf Sun, 04/07/2024 - 18:45 April 7, 2024 — Strategies such as earning points or small amounts of money encouraged people at high risk for heart disease or stroke to increase their daily walking by about 10% and sustain the increase for a year, according to research being presented at the American College of Cardiolog y’s Annual Scientific Session.
Med Page Today
APRIL 7, 2024
(MedPage Today) -- ATLANTA -- The SGLT2 inhibitor empagliflozin (Jardiance) did not exactly prevent deaths and heart failure (HF) events when initiated atop other standard therapies for acute myocardial infarction (MI), the EMPACT-HF trial found.
DAIC
APRIL 7, 2024
milla1cf Sun, 04/07/2024 - 18:09 April 7, 2024 — Among patients at high or very high risk for a heart attack or stroke, the addition of the investigational drug lerodalcibep to standard cholesterol-lowering medication for one year reduced LDL, or “bad” cholesterol, levels by more than half on average, compared with a placebo. In addition, 90% of patients treated with lerodalcibep, versus 16% of those on placebo, attained the newer, more stringent guideline-recommended LDL targets set by the Amer
Med Page Today
APRIL 7, 2024
(MedPage Today) -- ATLANTA -- An interatrial shunt failed to provide a clinical benefit to people with heart failure (HF) overall in the RELIEVE-HF trial, though actual harm or benefit seemed to hinge on the patient's left ventricular ejection.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
DAIC
APRIL 7, 2024
mtaschetta-millane Sun, 04/07/2024 - 18:43 April 7. 2024 — A single subcutaneous injection of the investigational drug zilebesiran , when added to existing treatment with a standard antihypertensive medication, reduced systolic blood pressure by between 4 to 12 mmHg on average at three months in patients whose blood pressure had remained uncontrolled despite compliance with their medication regimen, according to a study presented at the American College of Cardiology ’s Annual Scientific Session
Med Page Today
APRIL 7, 2024
(MedPage Today) -- ATLANTA -- Weight loss and heart failure benefits with semaglutide (Wegovy) extended to patients with obesity-related heart failure with preserved ejection fraction (HFpEF) who have type 2 diabetes, the STEP-HFpEF DM trial showed.
Cardiovascular Update brings together the best content for cardiovascular medicine professionals from the widest variety of industry thought leaders.
HCPLive
APRIL 7, 2024
Veraprapas Kittipibul, MD, discusses a study examining costs associated with heart failure hospitalization among patients with HFrEF or HFpEF from within the GWTG-HF registry.
American College of Cardiology
APRIL 7, 2024
Ticagrelor monotherapy following one month of dual antiplatelet therapy (DAPT) outperforms 12-month DAPT (aspirin and ticagrelor) post PCI for reducing clinically meaningful bleeding with no increased thrombotic risk, according to the results of the ULTIMATE-DAPT study, presented during a Late Breaking Clinical Trial session at ACC.24 and published simultaneously in The Lancet.
NEJM Journal Watch - Cardiology
APRIL 7, 2024
In a randomized, controlled trial, semaglutide resulted in greater weight loss, improved symptoms, and fewer serious adverse events compared with placebo.
American College of Cardiology
APRIL 7, 2024
The goal of the DanGer Shock trial was to compare the safety and efficacy of Impella CP on top of standard care compared with standard care alone among patients with ST-segment elevation myocardial infarction (STEMI) and cardiogenic shock.
HCPLive
APRIL 7, 2024
Alberto Foà, MD, PhD, discusses a PARAGON-HF analysis from ACC.24 examining treatment-related hypotension in people with HFmrEF/HFpEF.
American College of Cardiology
APRIL 7, 2024
The goal of the ULTIMATE-DAPT trial was to compare the safety and efficacy of ticagrelor monotherapy compared with dual antiplatelet therapy (DAPT) with aspirin and ticagrelor for 12 months following completion of 1-month DAPT for patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS).
HCPLive
APRIL 7, 2024
Plozasiran demonstrates a 74% reduction in triglyceride levels at 24 weeks in patients with severe hypertriglyceridemia in the phase 2b SHASTA-2 trial.
American College of Cardiology
APRIL 7, 2024
The goal of the REDUCE-AMI trial was to evaluate the potential benefit of beta-blockade following acute myocardial infarction (AMI) in patients with preserved left ventricular ejection fraction (LVEF) in the modern era of coronary revascularization and medical therapy.
The New England Journal of Medicine
APRIL 7, 2024
Transcatheter aortic-valve implantation (TAVI) has become the dominant, if not default, therapy for patients with severe, symptomatic aortic stenosis who are at intermediate, high, or prohibitive risk for surgical aortic-valve replacement (SAVR). Several randomized trials have shown that TAVI in patients at low surgical risk is either noninferior or.
American College of Cardiology
APRIL 7, 2024
Twelve weeks of daily smartphone messages, designed to cultivate spirituality and promote reflection, was associated with a reduction in systolic blood pressure (BP) and improvement in flow-mediated dilation (FMD).
Journal of Cardiothoracic Surgery
APRIL 7, 2024
Pulmonary embolism is the most common cardiovascular disease after myocardial infarction and stroke. Konstantinides (Eur Heart J 41(4):543–603, 2020) Current guidelines categorize patients with PE as being at.
American College of Cardiology
APRIL 7, 2024
Long-term treatment with beta-blockers may not lower the risk of death or myocardial infarction (MI) in patients with MI, a preserved left ventricular ejection fraction (LVEF) of ≥50% and coronary artery disease, according to the results of the REDUCE-AMI study, presented during a Late-Breaking Clinical Trial session at ACC.24 and published simultaneously in the New England Journal of Medicine.
Journal of Cardiothoracic Surgery
APRIL 7, 2024
This study aimed to elucidate the methodology and assess the efficacy of the aortic arch inclusion technique using an artificial blood vessel in managing acute type A aortic dissection (ATAAD).
American College of Cardiology
APRIL 7, 2024
A substantial gap was found between the self-reports of cardiovascular disease (CVD) by former players in the National Football League (NFL) and a "surprisingly high" prevalence of hypertension, with a "significant discrepancy between participants' awareness and observed disease prevalence," according to the findings.
Journal of Cardiothoracic Surgery
APRIL 7, 2024
Although risk factors for unsuccessful Maze procedure have been demonstrated, an appropriate patient selection is still controversial. In our institute, Maze procedure is indicated for those whom normal sinus.
American College of Cardiology
APRIL 7, 2024
Implantation of the Impella CP micro-axial flow pump may increase survival at six months among patients with STEMI complicated by cardiogenic shock (CS), according to the results of the DanGer Shock study.
All About Cardiovascular System and Disorders
APRIL 7, 2024
Transcript of the video: Now we will discuss a chest X-ray showing antler sign in pulmonary venous hypertension. For a change, first we will see the picture of a stag, with antlers. You can see the antlers here. So, the shape of the upper lobe vessels in venous hypertension, pulmonary venous hypertension, will be resembling the antlers of the stag. That is why, the name antler sign has been given.
American College of Cardiology
APRIL 7, 2024
The increasing need for cardiovascular clinicians to be equipped with the business know-how to navigate the rapidly evolving practice landscape is the focus of the Business of Cardiology Intensive Sessions at ACC.24.
Frontiers in Cardiovascular Medicine
APRIL 7, 2024
Congenital heart disease is a prevalent birth defect, accounting for approximately one-third of major birth defects. The challenge lies in early detection, especially in underdeveloped medical regions where a shortage of specialized physicians often leads to oversight. While standardized chest x-rays can assist in diagnosis and treatment, their effectiveness is limited by subtle cardiac manifestations.
American College of Cardiology
APRIL 7, 2024
Drs. Kim Eagle, Dharam Kumbhani, Payal Kohli, and Ajay Kirtane debate and discuss the outcomes of the trials presented on day 2 at ACC.24 including REDUCE-AMI (0:35), DanGer-Shock (3:28), ULTIMATE-DAPT (6:17), and TACT2 (10:04).
Frontiers in Cardiovascular Medicine
APRIL 7, 2024
Transcatheter aortic valve replacement (TAVR) has increasingly become a safe, feasible, and widely accepted alternative surgical treatment for patients with severe symptomatic aortic stenosis. However, the incidence of conduction abnormalities associated with TAVR, including left bundle branch block (LBBB) and high-degree atrioventricular block (HAVB), remains high and is often correlated with risk factors such as the severity of valvular calcification, preexisting conditions in patients, and pr
American College of Cardiology
APRIL 7, 2024
Edetate disodium-based chelation does not lead to improved outcomes in patients with diabetes who had previously suffered a myocardial infarction (MI), according to the results of the TACT2 study, presented during a Late-Breaking Clinical Trial session.
HCPLive
APRIL 7, 2024
Muthiah Vaduganathan, MD, MPH, discusses a presentation from ACC.24 assessing the effects of dapagliflozin across a range of left ventricular hypertrophy from DELIVER.
American College of Cardiology
APRIL 7, 2024
Generous contributions from ACC members around the world are helping to develop solutions for some of the biggest challenges of today, including inspiring and encouraging the next generation of leaders, educators, clinicians and scientists and tangibly addressing the global burden of cardiovascular disease.
HCPLive
APRIL 7, 2024
REDUCE-AMI concluded beta-blockers show no significant benefit following myocardial infarction among patients with normal left ventricular ejection fraction
American College of Cardiology
APRIL 7, 2024
The goal of the B-Free trial was to evaluate restrictive benzodiazepine use compared with liberal benzodiazepine use among patients undergoing cardiovascular surgery.
All About Cardiovascular System and Disorders
APRIL 7, 2024
Transcript of the video: Now I am going to describe Ashman Phenomenon in atrial fibrillation, which is responsible for a long and short sequence followed by a wide QRS, in atrial fibrillation noted on ECG, which may resemble a ventricular ectopic beat. This is the diagrammatic representation of Ashman phenomenon. You have sequences of AF beats, and a long cycle occurs, followed by a short cycle.
American College of Cardiology
APRIL 7, 2024
The goal of the TACT2 trial was to determine the potential clinical benefit of the chelating agent edetate disodium (EDTA) in older adults with a history of myocardial infarction (MI) and diabetes mellitus (DM).
Med Page Today
APRIL 7, 2024
(MedPage Today) -- ATLANTA -- Cardiology's bid to escape what many see as burdensome requirements for board certification maintenance under the American Board of Internal Medicine (ABIM) is well underway, a panel reported at the American College.
American College of Cardiology
APRIL 7, 2024
The goal of the SMART trial was to evaluate a self-expanding valve compared with a balloon-expandable valve among patients with aortic stenosis and a small aortic annulus undergoing treatment with transcatheter aortic valve replacement (TAVR).
Expert insights. Personalized for you.
115 
Let's personalize your content